William Blair Maintains Buy Rating for Solid Biosciences, Raises Price Target to $15.44.

William Blair analyst Sami Corwin maintains a Buy rating for Solid Biosciences, citing the company's strong potential. Corwin has an average return of 0.2% and a 40.57% success rate on recommended stocks. The analyst consensus is a Strong Buy with a price target of $15.44. Solid Biosciences has a one-year high of $10.37 and a one-year low of $2.41. The company has an average volume of 1.67M.

Solid Biosciences Inc. (SLDB) continues to attract favorable attention from Wall Street analysts, with William Blair analyst Sami Corwin maintaining a Buy rating for the company. Corwin's recommendation is backed by the company's robust pipeline of genetic medicines for neuromuscular and cardiac diseases, as well as its strong cash position.

Corwin, known for his 40.57% success rate on recommended stocks with an average return of 0.2%, has cited Solid Biosciences' potential as a key factor in his decision. The analyst consensus is a Strong Buy, with a price target of $15.44. This optimism is reflected in the company's stock price, which has seen a one-year high of $10.37 and a one-year low of $2.41, with an average trading volume of 1.67M shares.

Solid Biosciences' second-quarter 2025 financial results, reported on August 12, 2025, highlighted the company's strong cash position, with $268.1 million in cash, cash equivalents, and available-for-sale securities [2]. The company's cash runway is anticipated to extend into the first half of 2027, providing a solid financial foundation for its clinical development programs.

The company's clinical pipeline is particularly noteworthy. As of August 12, 2025, 15 participants have been dosed in the Phase 1/2 INSPIRE DUCHENNE trial, with participant dosing ongoing and no treatment emergent severe adverse events observed [2]. The company expects to initiate a separate randomized, double-blind, placebo-controlled trial of SGT-003 outside the United States in the fourth quarter of 2025, aiming to support potential global regulatory authorizations.

Additionally, Solid Biosciences expects to initiate a Phase 1b clinical trial of SGT-212, an investigational gene therapy for Friedreich's Ataxia (FA), in the fourth quarter of 2025. The company also received FDA Fast Track designation for SGT-501, a first-in-class gene therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) [2]. SGT-501 previously received Orphan Drug and Rare Pediatric Disease designations from the FDA.

The company's platform technologies, including its proprietary capsid AAV-SLB101, have been well tolerated in clinical trials and have over 25 agreements or licenses for use with academic labs, institutions, and corporations [2]. This strong pipeline and robust cash position have analysts optimistic about Solid Biosciences' future prospects.

References:
[1] https://www.finanznachrichten.de/nachrichten-aktien/solid-biosciences-inc.htm
[2] https://www.biospace.com/press-releases/solid-biosciences-reports-second-quarter-2025-financial-results-and-provides-business-updates